STOCK TITAN

Regeneron’s Andrew J. Murphy sells 5,011 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. (REGN) Co-Chief Scientific Officer Andrew J. Murphy sold 5,011 common shares on November 17, 2026, at reported per-share prices ranging from $949.69 to $964.36. The sales were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted May 7, 2026. On November 16, he exercised options for 17,000 shares at $381.92 per share; 11,989 common shares were delivered or withheld for payment of exercise price or tax liability. The filing also lists 4,414 shares held indirectly through a 401(k) Plan.

Insider MURPHY ANDREW J
Role Co-Chief Scientific Officer
Sold 5,011 shs ($4.80M)
Approx. gross sale proceeds $4.80M
Approx. exercise cost $6.49M
Type Security Shares Price Value
Sale Common Stock F1 93 $949.69 $88K
Sale Common Stock F1, F2 74 $950.61 $70K
Sale Common Stock F1, F3 298 $951.75 $284K
Sale Common Stock F1, F4 220 $952.75 $210K
Sale Common Stock F1, F5 671 $953.69 $640K
Sale Common Stock F1, F6 313 $954.45 $299K
Sale Common Stock F1, F7 313 $955.48 $299K
Sale Common Stock F1, F8 346 $956.70 $331K
Sale Common Stock F1, F9 202 $957.53 $193K
Sale Common Stock F1, F10 244 $958.27 $234K
Sale Common Stock F1, F11 506 $959.45 $485K
Sale Common Stock F1, F12 257 $960.65 $247K
Sale Common Stock F1, F13 584 $961.45 $561K
Sale Common Stock F1, F14 295 $962.70 $284K
Sale Common Stock F1, F15 255 $963.60 $246K
Sale Common Stock F1, F16 340 $964.36 $328K
Exercise Non-Qualified Stock Option (right to buy) F1, F17 17,000 $0.00 $0.00
Exercise Common Stock F1 17,000 $381.92 $6.49M
Exercise Price or Tax Liability Common Stock F1 11,989 $960.02 $11.51M
Holding Common Stock -- -- --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 options (Direct); Common Stock — 46,779 shares (Direct); Common Stock — 4,414 shares (Indirect, By 401(k) Plan)
Footnotes (17)
  1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
  2. F2. Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  3. F3. Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  4. F4. Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  5. F5. Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  6. F6. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  7. F7. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  8. F8. Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price
  9. F9. Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  10. F10. Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  11. F11. Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  12. F12. Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  13. F13. Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  14. F14. Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  15. F15. Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  16. F16. Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  17. F17. The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Common shares sold 5,011 shares November 17, 2026
Reported sale prices $949.69–$964.36 per share November 17, 2026; several sale entries report volume-weighted average prices
Options exercised 17,000 shares November 16, 2026
Option exercise price $381.92 per share November 16, 2026
Shares delivered or withheld 11,989 shares November 16, 2026; for payment of exercise price or tax liability
Indirect shares held 4,414 shares Held by a 401(k) Plan as listed on November 16, 2026
Rule 10b5-1(c) regulatory
"plan intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
volume-weighted average price financial
"Represents volume-weighted average price of sales"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Non-Qualified Stock Option technical
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did Andrew J. Murphy sell, and at what prices?

Andrew J. Murphy sold 5,011 REGN common shares on November 17, 2026, at reported per-share prices ranging from $949.69 to $964.36. Several sale entries report volume-weighted average prices. The sales were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted May 7, 2026.

How many REGN options did Andrew J. Murphy exercise?

Andrew J. Murphy exercised options covering 17,000 common shares at $381.92 per share on November 16, 2026. That day, 11,989 common shares were delivered or withheld for payment of exercise price or tax liability. He reported sales of 5,011 shares the following day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MURPHY ANDREW J

(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD

(Street)
TARRYTOWN NEW YORK 10591

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)17,000A$381.9263,779D
Common Stock11/16/2026F(1)11,989D$960.0251,790D
Common Stock11/17/2026S(1)93D$949.6951,697D
Common Stock11/17/2026S(1)74D$950.61(2)51,623D
Common Stock11/17/2026S(1)298D$951.75(3)51,325D
Common Stock11/17/2026S(1)220D$952.75(4)51,105D
Common Stock11/17/2026S(1)671D$953.69(5)50,434D
Common Stock11/17/2026S(1)313D$954.45(6)50,121D
Common Stock11/17/2026S(1)313D$955.48(7)49,808D
Common Stock11/17/2026S(1)346D$956.7(8)49,462D
Common Stock11/17/2026S(1)202D$957.53(9)49,260D
Common Stock11/17/2026S(1)244D$958.27(10)49,016D
Common Stock11/17/2026S(1)506D$959.45(11)48,510D
Common Stock11/17/2026S(1)257D$960.65(12)48,253D
Common Stock11/17/2026S(1)584D$961.45(13)47,669D
Common Stock11/17/2026S(1)295D$962.7(14)47,374D
Common Stock11/17/2026S(1)255D$963.6(15)47,119D
Common Stock11/17/2026S(1)340D$964.36(16)46,779D
Common Stock4,414IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$381.9211/16/2026M(1)17,000 (17)12/16/2026Common Stock17,000$0.00D
Explanation of Responses:
1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
2. Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
3. Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
4. Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
5. Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
6. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
7. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
8. Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price
9. Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
10. Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
11. Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
12. Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
13. Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
14. Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
15. Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
16. Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
17. The stock option award vested in four equal annual installments, commencing one year after the date of grant.
/s/ Andrew Murphy11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading